Transcript — The Drive — Dave Feldman
Transcript of episode 19 of The Drive with Peter Attia, released October 8, 2018.
#19 – Dave Feldman: stress testing the lipid energy model
“I am on a journey of science, not of advocacy: I’m going to be quite a skeptic.” —Dave Feldman
#210 – Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.
“I think we should advise people to measure Lp(a); that would be a gigantic step.” —Benoît Arsenault
#24 – Tom Dayspring, M.D., FACP, FNLA – Part V of V: Lp(a), inflammation, oxLDL, remnants, and more
“Use the correct terminology with everything.” –Tom Dayspring
#23 – Tom Dayspring, M.D., FACP, FNLA – Part IV of V: statins, ezetimibe, PCSK9 inhibitors, niacin, cholesterol and the brain
“This is what it ultimately comes down to – and it’s the way you practice – you’ve got to individualize everything.” –Tom Dayspring
#22 – Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins
“Here’s something that’s going to shock you: in an average person, anywhere from 30 to 60 percent of the cholesterol in that LDL particle arrived via an HDL particle.” –Tom Dayspring
Narrative glossary: lipids
A companion post for the podcast episodes with Thomas Dayspring, M.D., FACP, FNLA (October 15-19, 2018).
Measuring cardiovascular disease risk and the importance of apoB
Millions of Americans schedule an annual physical health examination. During their visit, many can expect to get their blood drawn for…
The straight dope on cholesterol – Part V
In this post we’ll address the following concept: Does the size of an LDL particle matter?
#129 – Tom Dayspring, M.D.: The latest insights into cardiovascular disease and lipidology
“Atherogenic lipoproteins are really the issue behind clinical atherosclerotic vascular disease. … The data has just become so overwhelming.” —Tom Dayspring